Research and Development Investment: Amgen Inc. vs ImmunityBio, Inc.

A Decade of Innovation: Amgen Inc. vs ImmunityBio, Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Amgen Inc. and ImmunityBio, Inc. have demonstrated contrasting strategies in their R&D expenditures. Amgen, a giant in the biotech industry, consistently invested heavily, with a peak in 2021, spending nearly 30% more than its 2014 figures. In contrast, ImmunityBio, a smaller player, showed a remarkable growth trajectory, increasing its R&D spending by over 14,500% from 2014 to 2023. This stark difference highlights the diverse approaches within the industry: while established companies like Amgen focus on sustaining innovation, emerging firms like ImmunityBio are rapidly scaling their research efforts. As the biotech sector continues to expand, these investment patterns offer a glimpse into the future of medical breakthroughs.